Rituximab as first line: an advent in pemphigus
نویسندگان
چکیده
منابع مشابه
Rituximab as a first-line preventive treatment in pediatric NMOSDs
OBJECTIVE No established therapeutic protocol has been proposed to date for childhood-onset neuromyelitis optica (NMO) spectrum disorders (NMOSDs). We report the response of 5 NMO immunoglobulin (Ig)G-positive pediatric cases to a standardized B-cell-targeted first-line immunosuppressive protocol with rituximab for prevention of relapses. METHODS Retrospective observational cohort study. RE...
متن کاملFirst-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids.
IMPORTANCE The main component of the first-line treatment of pemphigus vulgaris is high doses of systemic corticosteroids, but adverse effects of these drugs are frequent and sometimes severe. Rituximab has shown effectiveness as a corticosteroid-sparing agent or in case of relapse. To our knowledge, the effectiveness of rituximab as a first-line treatment without systemic corticosteroids has n...
متن کاملFirst-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus.
Pemphigus is a life-threatening autoimmune blistering disease. Systemic corticosteroids have been the mainstay and first-line treatment with success. However, longterm use of corticosteroids results in significant morbidities and mortalities. Much effort has been focused on searching alternative or corticosteroids-sparing agents. Rituximab (MabTheraTM; Roche, Basle, Switzerland), a chimeric ant...
متن کاملRituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura
Objective To investigate the efficacy and safety of rituximab (RTX) as first-line treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Methods Twenty-five patients with acute aTTP and/or severe a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency were admitted to our centre from April 2009 to March 2015. Fourteen patients received ...
متن کاملRituximab in the Treatment of Pemphigus Vulgaris
INTRODUCTION Rituximab is increasingly used in patients with pemphigus vulgaris (PV) who are nonresponders to conventional therapy. METHODS A PubMed search was conducted using the words pemphigus vulgaris and rituximab therapy from papers published between 2000 and 2012. Two protocols were used. In the lymphoma protocol, patients received four weekly infusions of rituximab (dose 375 mg/m(2))....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Research in Dermatology
سال: 2019
ISSN: 2455-4529
DOI: 10.18203/issn.2455-4529.intjresdermatol20190249